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A B S T R A C T
Additive manufacturing processes used to create regenerative bone tissue engineered implants are not bio-
compatible, thereby restricting direct use with stem cells and usually require cell seeding post-fabrication.
Combined delivery of stem cells with the controlled release of osteogenic factors, within a mechanically-strong
biomaterial combined during manufacturing would replace injectable defect fillers (cements) and allow perso-
nalized implants to be rapidly prototyped by 3D bioprinting.
Through the use of direct genetic programming via the sustained release of an exogenously delivered tran-
scription factor RUNX2 (delivered as recombinant GET-RUNX2 protein) encapsulated in PLGA microparticles
(MPs), we demonstrate that human mesenchymal stromal (stem) cells (hMSCs) can be directly fabricated into a
thermo-sintered 3D bioprintable material and achieve effective osteogenic differentiation. Importantly we ob-
served osteogenic programming of gene expression by released GET-RUNX2 (8.2-, 3.3- and 3.9-fold increases in
OSX, RUNX2 and OPN expression, respectively) and calcification (von Kossa staining) in our scaffolds. The
developed biodegradable PLGA/PEG paste formulation augments high-density bone development in a defect
model (~2.4-fold increase in high density bone volume) and can be used to rapidly prototype clinically-sized
hMSC-laden implants within minutes using mild, cytocompatible extrusion bioprinting.
The ability to create mechanically strong 'cancellous bone-like’ printable implants for tissue repair that
contain stem cells and controlled-release of programming factors is innovative, and will facilitate the devel-
opment of novel localized delivery approaches to direct cellular behaviour for many regenerative medicine
applications including those for personalized bone repair.
1. Introduction
Additive manufacturing of custom, defect-matched implants for
regenerative medicine has significantly developed over the last decade
[1]. For bone tissue engineering these approaches employ ceramic and
polymeric materials to enable bone-like mechanically strong scaffolds
to be generated, however the manufacturing process may not be bio-
compatible (using high-temperatures, UV-light or organic solvents) [2].
As such only acellular implants are created and the incorporation of
stem cells or therapeutic molecules can only occur post-fabrication.
This prevents uniform seeding, patterning of cells or molecules to
produce functionally complex tissues and long-term delivery is in-
hibited; thus bio-inductive strategies are often not effective or have less
controlled activity [1]. Development of production processes which can
be used intraoperatively; with cells and biomolecules directly included
in the process is therefore vital for their clinical use.
Successful regenerative medicine strategies often rely on exquisite
control of the biological microenvironment and supplementation of
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extrinsic therapeutic molecules to orchestrate cellular behaviour.
Cellular processes like migration, proliferation, adhesion and differ-
entiation occur in response to chemical cues present within the mi-
croenvironment such as interaction with extracellular matrix (ECM)
and stimulation with morphogens or growth factors (GFs) [3,4]. These
macromolecules trigger intracellular signal transduction pathways,
with complex cross-talk between signalling cascades and eventual
programming of cell behaviour through transcription factors (TFs)
[4–6]. Directed cell differentiation can be achieved through the use of
chemical induction or exogenous GFs or hormones, which might have
non-specific pleiotropic effects. Therefore, there is a need for more ef-
ficient and targeted molecules that can be used in regenerative medi-
cine. TFs can provide specific regulatory effect, which is considered
ideal for cell fate; however, these TFs are difficult to deliver in-
tracellularly.
Glycosaminoglycan-binding Enhanced Transduction (GET) peptides
[7–14] are delivery peptides that enhance transduction and endosomal
escape of cargoes in cells. GET peptides contain Heparan Sulphate (HS)
binding motifs that enhance binding to cell surface glycosaminoglycans
(GAGs) which concentrate the cargo on cell membranes, combined with
cell penetrating peptide (CPP) and endosomal escaping peptide ele-
ments to mediate uptake and escape, respectively. We have previously
published the enhanced delivery characteristics and versatility of GET
peptides, used as synthesized L-amino acid peptides or recombinant
protein fusions to deliver recombinant proteins [9] [13], nucleic acids
(pDNA, mRNA, siRNA) [7,11,12] and magnetic nanoparticles [14].
Our recent work has shown that recombinant TFs can be expressed,
purified and delivered efficiently to control cell behaviour for various
applications [7]. This system can be utilized to regenerate tissues if
these molecules are supplied at functional dose, duration and location.
Osteogenic TF RUNX2 (also called Core-binding factor alpha, CBFa1) is
essential for osteoblast commitment, differentiation, matrix production,
and mineralization during bone formation [15]. RUNX2 regulates
downstream genes that determine the osteoblast phenotype and con-
trols the expression of osteogenic marker genes such as ALP, OP, OSX,
COL1A1 (type-I collagen), BSP, and OCN [16–19] in response to phy-
siological signals [20].
We previously showed that GET-RUNX2 can be used to direct
human Mesenchymal Stromal Cells (hMSCs) towards osteogenesis, re-
moving the need to use pleiotropic compounds (such as dex-
amethasone), or GFs (such as BMP2) which may trigger unwanted off-
target cellular responses. However, this TF needs to be supplied at a
specific dose over a period of time for osteogenic induction [9].
Importantly, we have also shown the utility of GET peptides in re-
generative medicine by delivering TFs RUNX2 and MYOD for osteo-
genesis and zonal myogenesis in three-dimensional gradients [9,21],
respectively. Moreover, GET peptides have been used to enhance the
delivery and transfection of nucleic acids for lung gene therapy and
bone regeneration in vivo [11,12]. The latter delivering GF genes to
enhance the repair of a critical size calvarial bone defect in rats [12].
Controlled and localized release of therapeutic molecules is one of
the main factors that affect tissue regeneration within a scaffold [22].
The combination of biomaterials (scaffolds component), cells and
therapeutic molecules can be used for localized and targeted re-
generation therapies [23]. Poly-(DL-lactic acid-co-glycolic acid)
(PLGA), which has been extensively studied as a degradable implant
material [24], was used as a scaffold to study bone regeneration given
its mechanical properties and enhanced mineralized tissue formation
from its osteoconductive properties [25]. It has been shown that mixing
PLGA with a plasticizer (such as Poly(ethylene glycol); PEG) will pro-
duce temperature-sensitive particles with a reduced glass transition
temperature (Tg) of 37 °C [26]. When these particles are mixed with an
aqueous carrier solution at room temperature an extrudable paste is
formed that can be moulded into any size or shape. Incubation of these
pastes at 37 °C, surrounded by aqueous fluid leads to thermoresponsive
liquid sintering and the formation of porous solid constructs [21–26].
These constructs can be engineered with mechanical properties which
are comparable to those of human cancellous bone [21–24,27–30].
Previous studies utilizing this material have shown that proteins
[23,25,26,27] and cells [21,23, 27] can tolerate the mixing and ex-
trusion processes while maintaining activity and viability, respectively.
Encapsulated proteins can be delivered over several weeks [26] and the
microporosity inherent to these constructs, may also have beneficial
effects on tissue ingrowth and angiogenesis in vivo.
Our recent study demonstrated that GET-tagged reporter peptides
(mRFP, red fluorescent protein) could be efficiently encapsulated and
its release controlled in PLGA microparticles (MPs) [13]. Moreover, this
delivery system could provide sustained release of GET peptides for at
least 7 days, without loss of transduction activity. In the current study,
we hypothesized that these MPs could be employed to provide a sus-
tained release system for TFs needed to promote osteogenesis of hMSCs.
Herein, we have utilized biomaterials, cells and a therapeutic re-
combinant molecule to demonstrate that a combined system can be
rapidly fabricated into mechanically strong osteogenic scaffolds or
implants. GET-RUNX2 (RUNX2) loaded MPs, mixed with modified
PLGA/PEG paste formulations was developed to provide a controlled
release delivery of an osteogenic TF, a compatible microenvironment
for the stem cells to generate new bone, and a system to deliver a
mechanically strong implantable material, both in vitro and in vivo.
In this study, we aimed to demonstrate the efficient encapsulation,
and release of active GET-RUNX2 protein from PLGA MPs which could
be combined in a mechanically strong, 3D printable material. An in-
novative combined approach could have significant impact on clinical
application of regenerative medicine in bone repair. Importantly, in-
corporation of viable hMSCs and a cell-fate programming system into a
bioprinting process to produce osteogenic living implants could be
demonstrated. The combination of this complete tractable system is the
novelty and significance of our system.
2. Materials and methods
2.1. Protein synthesis and FITC tagging
CPP (eight arginine, termed 8R) and heparin binding domain (HBD,
termed P21), which compose the Glycosaminoglycan – binding en-
hanced transduction (GET) system were used to tag the human RUNX2
ORF to allow production of P21-RUNX2-8R protein [9]. cDNA con-
structs containing 8R, RUNX2 and P21 sequences were synthesized de
novo (Eurofins MWG Operon, Ebersberg, Germany) and cloned into
pGEX6-P1 expression vector (Novagen Watford, U.K.) [9]. Recombinant
protein was expressed and purified as previously described in [28]. For
protein tracking, P21-RUNX2-8R was tagged with FITC using NHS-
Fluorescein as per manufacturer's instructions (Thermo Scientific) at
1:50 protein: label molar ratio and purified/buffer exchanged to PBS
using Bio-Spin P-6 spin columns (Bio-Rad, Watford, UK).
2.2. PLGA microparticle fabrication
Poly (D,L-lactide-co-glycolide, (PLGA) LA:GA ratio: 50:50; Mw
52 kDa, Evonik Industries, USA) MPs were formed using solid-in-oil-in-
water (S/O/W) emulsion as previously described [13,29]. Briefly, 1 mg
of P21-RUNX2-8R, was mixed with 0.5 mg PEG 6000 (Sigma-Aldrich,
UK) and 0.25 mg L-Histidine (Sigma-Aldrich, UK) and freeze dried
overnight. Blank MPs were prepared by freeze drying 0.5 mg PEG 6000
only. PLGA was dissolved in dichloromethane (DCM, Fisher, UK)
(200 mg of PLGA was dissolved in 1.5 ml DCM) and added to the freeze
dried powder. The theoretical GET-RUNX2 loading was 1 mg in 200 mg
PLGA (0.5%) The solution was then mixed by vortexing. Two hundred
microliters of phosphate buffered saline (PBS, Gibco, UK) was added to
the solution and vortexed to produce a homogenous emulsion. Four
millilitres of 0.25% (w/v) methylcellulose (Sigma-Aldrich, UK) solution
was then added to the mixture and vortexed again. The resultant
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emulsion was then poured into 400 ml of distilled water; and the re-
sultant (S/O/W) emulsion was left stirring for 3 h to allow DCM eva-
poration. The hardened MPs were then collected by centrifugation and
washed three times with distilled water. The obtained MPs were then
freeze dried (Edwards Modulyo D IMA Edwards, UK) for 24 h.
2.3. Extrusion bioprinting
A RegenHU 3D Discovery system (Switzerland) was used for 3D
printing with Huber Pilot ONE temperature controller (Switzerland).
PLGA/PEG particles (≤50 μm) were mixed by spatula with different
carriers, cells and microparticles at 4 °C before being transferred into a
sterile syringe. Mixing was performed until a homogenous colour (of
the phenol-red cell culture media) was achieved as previously [30].
Syringes were placed into the printer mount and allowed to equilibrate
with the printing temperature (25 °C). During printing, the pressure was
manually adjusted (1–3 bar) to ensure adequate flow of material
through the 20 gauge (0.61 mm) tapered syringe tip (Adhesive dis-
pensing Ltd. UK). The print speed varied between 20 and 60 mm/s.
BioCAD software (RegenHU) was used to design the lattice structure to
be printed. Dissection microscope Nikon SMZ1500 was used to image
the printed structures. For 3D printing of the L5 vertebra, SLS files were
downloaded from: http://www.thingiverse.com/thing:781206. For L5
vertebrate; PLGA/PEG with Pluronic F-127 (PF127) 18% (with 1% Tri-
acetin) 1:1.5 ratio was mixed and loaded to the printer, the printing
temperature was 25 °C.
2.4. Cell seeding pre-fabrication
Cells were mixed with the carrier (18% PF-127 with 1% Tri-acetin)
with final density of 1 × 107/ml and mixed with PLGA/PEG particles in
1:1.5 (PLGA/PEG:carrier, w/v) ratio at 4 °C as described previously
[30]. The resultant mixture was then loaded to the mould or printing
syringe and heated to 25 °C. The mixture was then printed, and sintered
at 37 °C for 30 min. The sintered scaffolds were then washed in cold PBS
for 45 min and then cultured in cell culture media.
2.5. Cell seeding post-fabrication
To ensure sterility, the scaffolds were treated with 1% antibiotic and
antimycotic solution for 20 min at 370C and washed extensively with
sterile PBS as previously described [13,31]. Fifty thousand cells in a
20 μl suspension was pipetted onto each sintered scaffold. The scaffolds
were incubated for 1 h at 37 °C, to allow attachment, prior to addition
of 1 ml media to each well.
2.6. Osteogenesis assay
DMEM: F12 media (Life technologies, Paisley, UK) supplemented
with 10% (v/v) fetal bovine serum, 2 mM L-glutamine, 100 units/ml
penicillin and 100 μg/ml streptomycin (Sigma) was used as the basal
media for osteogenic media. Fifty thousand cells per scaffold (con-
taining blank MPs or P21-RUNX2-8R loaded MPs) were seeded and
cultured for 4 weeks depending on the experiment with appropriate
media. 50 μg/ml L-Ascorbic acid 2-phosphate sesquimagnesium salt
hydrate (Sigma) and 10 mM β glycerophosphate disodium salt penta-
hydrate (Acros Organics) were added to the basal media for osteo-
permissive medium (OP). To make osteo-inductive media (OI), 100 nM
Dexamethasone (Sigma) was added to the osteo-permissive (OP)
medium. Cells were cultured for 3–4 weeks for complete osteogenesis.
Medium was changed every other day.
2.7. Cell viability assay
PrestoBlue® cell viability assays (Invitrogen Life Sciences, UK) were
performed on day 3, 6 and 9 post-seeding on three scaffolds per time
point. Each scaffold was submerged in 900 μl of media and 100 μl of
PrestoBlue was added to each well and mixed. The scaffolds were then
incubated at 37 °C for 2 h. Three 100 μl media samples were taken from
each well and were read on Tecan plate reader with the excitation
wavelength set to 560 nm and the emission wavelength set at 590 nm.
Blank sample readings were subtracted and results were compared with
corresponding standard curve of known cell numbers to calculate the
number of cells per scaffold.
2.8. In vivo bone defect assay and μCT
hMSC populations were selected by magnetic separation (STRO-
1+) from adherent mononuclear cell fractions from human bone
marrow obtained during routine knee/hip replacement surgeries with
full ethical approval and informed consent from the patients in ac-
cordance with approval from Southampton & South West Hampshire
Local Research Ethics Committee, UK (Ref: 194/99/w). Briefly, bone
marrow aspirate was thinned with basal media (DMEM supplemented
with 10% (v/v) FBS, 1% (v/v) sodium pyruvate, 1% (v/v) non-essential
amino acids, 1% (v/v) penicillin-streptomycin, 1% (v/v) L-glutamine,
and layered onto Lymphoprep density gradient media (Stem Cell
Technologies). Following centrifugation at 800 ×g for 40 min, the in-
termediate interface of mononuclear cells was removed and washed
three times with media. These cells were then selected for the marker
STRO-1 using an in-house STRO-1 antibody (original hybridoma cour-
tesy of Dr. Beresford, University of Bath, UK) using a MACS kit from
Miltenyi Biotech as previously detailed [32]. Only adherent STRO-1+
cells were cultured. Cells from two patients were used in two separate
experiments. Scaffold containing P21-mRFP-8R or P21-RUNX2-8R MPs
were cut into approximately 1 mm3 sized pieces and 1-3 × 104 STRO-
1+ hMSCs were added to each scaffold. Cells were incubated on the
scaffold at 37 °C, 5% CO2 for 3–4 days. All in vivo studies were un-
dertaken following approval from the local Animal Welfare and Ethics
Review Board (AWERB) University of Southampton and carried out in
accordance with the guidelines and regulations stipulated in the Ani-
mals (Scientific Procedures) Act, UK 1986 under the approved Home
Office Project license (PPL 96B16FBD). All mice were raised within the
University of Southampton Biomedical Research Facility and were
housed in appropriate environments in rooms maintained at 22 ± 2 °C
with a 12 h light: 12 h dark cycle. Eight week old male athymic nude
BALB/c mice were used for the study with 4–6 animals per group per
patient. A 1 mm drill-hole defect was made in the right distal femur,
and then a single 1 mm3 scaffold piece with hMSCs was added to the
hole. After surgery and at 2 weekly intervals, mice were anaesthetized
using isoflurane inhalation. Femora were scanned using a Skyscan 1176
in vivo micro(μ)CT scanner (Bruker microCT, Kontich, Belgium). All
scans were taken at 65 kV, 385 μA with 1 mm aluminium filter, and 0.7°
rotation step. Individual 2D cross-sectional images were reconstructed
using Bruker NRecon software version 1.6.10.2. Voxel resolution was
35 μm. All reconstructed bones were set to the same orientation with
the transverse plane perpendicular to the long axis of the bone using
Bruker Dataviewer software. For each animal, the scan at the time of
surgery (week 0) was used as a reference, and subsequent scans were
aligned to this scan using 3D Registration in Dataviewer. A 1 mm dia-
meter volume of interest centred on the defect hole at week 0, was used
on all subsequent scans to determine bone volume and density at the
defect site. The depth of the defect is the thickness of the cortical bone
(approx. 250 μm). The images are semi-transparent and represent the
bone density for the entire 3D reconstruction. High density bone was
defined based on the intensity of signal measured by μCT as we have
previously published [33] (lowest density bone set at 0.25 g/cm3).
2.9. Statistical analysis
Statistical analysis was carried out using GraphPad Prism (version
7). For ALP assays the statistical significance was determined using one-
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way ANOVA with Holm-Sidak post hoc test for ALP study. For gene
expression analyses. Proliferation and mechanical testing data was
analysed by two-way ANOVA and Tukey's test assuming confidence
levels of 95% (p < .05). For mechanical testing the homogeneity of
variances across experimental groups was determined by Levene's test.
Appropriate post hoc procedures were used after one way ANOVA for
pairwise comparison of experimental groups. In cases of equal variance
Tukey's procedure was applied, whilst the Games-Howell procedure
was used for cases of unequal variance. For the in vivo study, sig-
nificance was determined using independent sample t-test in SPSS
version 25 (IBM, Woking, UK). Results were considered significant at
p < .05, mean values are given plus or minus the standard deviation
(SD) or Standard error or the mean (SE).
3. Results
3.1. Efficient encapsulation and controlled release of GET-RUNX2
PLGA MPs were fabricated using an optimized S/O/W double
emulsion process and encapsulated GET-tagged RUNX2 protein (P21-
RUNX2-8R, termed GET-RUNX2). PBS was added to the formulation to
increase porosity thereby accelerating the protein release [13]. PBS acts
as a porogen, which is expected to increase MP porosity and generate
channels within and on the MP surface. Porous MPs were needed to
accelerate the GET-RUNX2 release as previously shown [13]. MPs
prepared using the S/O/W methodology showed spherical structure
with smooth and porous surface due to the addition of PBS (Fig. 1A&B).
Porosity of the fabricated PLGA MPs was assessed visually using SEM
images and these were similar to those in our previous work [13]. The
mean diameter of the MPs was 36.5 ± 7.2 μm, with average loading
efficiency of 58.4 ± 7.0% (generating 2.9 ± 0.2 μg per mg of PLGA
MPs) (Fig. 1C & S1). P21-RUNX2-8R MP dose was optimized to obtain
release quantities matching or greater than the dose needed (60 μg
GET-RUNX2 during the first week) to initiate osteogenic differentiation
of hMSCs [9]. The release profile showed comparable GET-RUNX2
quantities (i.e. 30 μg in the burst release phase and a further 30 μg over
5 days) (Fig. 1D&E). Moreover, this represented more than 90% of the
protein loaded in MPs, which confirmed that minimal protein is re-
leased after the first week. This was important as RUNX2 activity is
needed predominantly during the early stages of osteogenesis, and
overexpression or prolonged activity of RUNX2 during later stages de-
lays matrix mineralization [34].
3.2. PLGA released GET-RUNX2 retains intracellular transcriptional
activity
As GET-RUNX2 can be encapsulated and released in osteogenic-in-
ductive quantities from fabricated PLGA MPs, it was crucial to de-
monstrate that it also retained its biological activity (both transducing
into cells via the GET peptides and retained transcriptional activity). We
previously demonstrated that PLGA MPs benefit from the inclusion of L-
Histidine during fabrication to maintain the macropinocytotic-activity
of GET peptides [13]. L-Histidine is needed to maintain complete ac-
tivity of GET peptides upon increased acidity in the microenvironment
Fig. 1. MP characterization and P21-RUNX2-8R-FITC in vitro release profile (pH 7.4 at 37 °C). MPs were fabricated using PLGA (50:50), loaded with P21-RUNX2-
8RFITC (0.5% (w/w)), mixed with PBS 0.1% (w/w) and L-Histidine 25% (w/w). (A, B) SEM analyses for MPs (scale bars represent (A) 100μm and (B) 10 μm). (C)
Summary of size characterization and corresponding loading efficiencies (n = 3). (D, E) Protein release quantified using Micro BCA assay kit. (D) Relative cumulative
protein release. (E) Cumulative protein quantity (using same data as D). Error bars indicate SD (n = 3).
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within the PLGA MPs [13]. The transduction activity of GET-RUNX2
was confirmed by comparing released protein to non-encapsulated
controls. To facilitate visualization, we labelled GET-RUNX2 with FITC
(NHS-fluorescein). Released GET-RUNX2-FITC was collected over the
7 day time course and was incubated with plated hMSCs to assess in-
ternalization (Fig. 2A), transduction (Fig. 2B&C) and transcriptional
activity (Fig. 2D). Importantly, we compared the released samples to
non-encapsulated ‘fresh’ controls diluted to the same final concentra-
tion (i.e. the released protein was quantified and compared against
fresh protein sample of the same concentration). Incubated cells were
then evaluated for transduction by fluorescence microscopy and flow
cytometry analyses (Fig. 2A&B). Fluorescent microscopy showed sig-
nificant GET protein internalization for the collected samples released
from PLGA MPs (Fig. 2A). Flow cytometry results showed high trans-
duction activity with relative transduction activity not statistically
different (~70% of ‘fresh’ GET-RUNX2 levels) for all the studied sam-
ples (Fig. 2B&C). Therefore it was clear that the released protein re-
tained their transduction activity throughout at least a 7 day release
period.
In order to study the transcriptional activity of the released GET-
RUNX2, the immediate transcriptional activation of a RUNX2-re-
sponsive luciferase reporter containing the transcriptional responsive
sequence from the OSTEOCALCIN (OCN) promoter (mOG2-Luc) was
tested (Fig. 2D), as used previously [9]. The activity of the released
GET-RUNX2 samples was compared with non-encapsulated ‘fresh’ GET-
RUNX2. Cells were exposed to the released GET-RUNX2 before and
after reporter transfection which generates the most pronounced tran-
scriptional activity as previously shown [9]. We observed that the re-
leased GET-RUNX2 (collected at day 1 and 2) induced mOG2-Luc re-
porter expression to a magnitude comparable to the ‘fresh’ GET-RUNX2
(i.e. 1.57 (± 0.51) fold verses 2.21 (± 0.21) fold respectively). Tran-
scriptional activity enhancement was not significant post-day 2 due to
the smaller amounts of GET-RUNX2 released. Although this assay is not
highly responsive, transcriptional enhancement was shown significant
for immediate activity above control untreated levels. These findings
clearly indicate that the released GET-RUNX2 retained its transduction
and transcriptional activity upon releasing from PLGA MPs.
Fig. 2. Retained transduction and transcriptional activity of released P21- RUNX2-8R. PLGA MPs were prepared using S/O/W method, loaded with P21- RUNX2-8R-
FITC (0.5% (w/w)). (A) Transduction activity of the released protein was assessed in hMSC monolayers. Representative fluorescence microscopy images of the hMSCs
treated for 24 h with the released P21-RUNX2-8R-FITC (Scale bar represents 100 μm) collected on the days indicated. (B) Flow cytometry histograms showing
cellular uptake of P21-RUNX2-8R-FITC in hMSCs. The green histograms are the released P21-RUNX2-8R-FITC, while the black histograms are fresh experimental
controls of P21-RUNX2-8R-FITC delivered at the same released concentrations (between 3 and 20 μg/ml)(the same fresh controls were used for day 5 and 7). Gates of
from control cells showing negative (left) and positive (right) cells. (C) Relative transduction activity of released P21- RUNX2-8R-FITC compared to fresh protein.
Values are the mean fluorescence intensity (MFI) per cell from flow cytometry. (D) Transcriptional activity of the released P21-RUNX2-8R-FITC measured using
mOG2-Luc RUNX2-responsive luciferase reporter gene assay. pRUNX2 (plasmid DNA, pSIN-RUNX2) transfection was used as a positive control. Values induced after
1 or 2 days transduction are presented. Error bars indicate SD (n = 3). ** p < .05. (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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3.3. PLGA/PEG scaffolds support hMSC attachment and proliferation
In order to generate a delivery vehicle for cells and MPs, and ca-
pacity for localized delivery of GET-RUNX2, scaffolds were prepared
aiming to incorporate the fabricated MPs with seeded cells on top or
within them. The goal was to finally incorporate the full system with
hMSCs and GET-RUNX2 MPs into a 3D bioprintable formulation.
Our previously developed temperature sensitive scaffold (composed
of PLGA/PEG) was used [13]. This system allows incorporation of PLGA
MPs with the PLGA/PEG scaffold particles that will sinter to form a
hard porous scaffold at 37 °C, whereas, at room temperature the mix-
ture remains as a paste. PLGA/PEG temperature sensitive particles were
prepared as previously detailed [13] (Fig. 3A). GET-RUNX2 loaded MPs
were mixed with PBS and the PLGA/PEG material before sintering, the
material was then loaded into PTFE moulds creating cylindrical scaf-
folds (3 mm depth x 6 mm diameter) and sintered for 2 h at 37 °C. Blank
MPs were used for non-loaded scaffold controls. Initially, hMSCs were
seeded on these sintered scaffolds and cultured for further studies.
PrestoBlue assay was performed on days 3, 6 & 9 to confirm cell me-
tabolism and therefore viability on scaffolds. The results demonstrated
that the scaffold is conducive for cell proliferation (i.e. cell number
increased from around 40,000 at day 3 to around 65,000 at day 9)
(Fig. 3B). SEM images showed a different surface morphology for cell-
seeded scaffolds (compared to non-seeded scaffold) with cells covering
the scaffolds with no vacant pores on the surface (Fig. 3C–H). This was
similar to previous analyses of cell attachment and growth on PLGA/
PEG scaffolds [26].
3.4. hMSCs differentiate in response to GET-RUNX2 released from PLGA
MPs
For hMSC osteogenic differentiation in vitro, ascorbic acid and β-
glycerophosphate are essential for final stages of bone nodule formation
by promoting collagen matrix production and providing inorganic
phosphate for mineralization, respectively. In order to test the effect of
GET-RUNX2 on bone differentiation, media containing these additives
(termed ‘osteo-permissive’, OP) was used during differentiation studies.
hMSCs were seeded on scaffolds containing either GET-RUNX2-loaded
MPs or blank MPs. Osteo-inductive media (OI) containing 100 nM
Dexamethasone (along with 50 μg/ml ascorbic acid and 10 mM β-gly-
cerophosphate) was used as a positive control on scaffolds containing
blank MPs. A full assessment of osteogenic differentiation was carried
Fig. 3. hMSCs attach and proliferate on PLGA/PEG scaffolds. (A) Schematic of scaffolds fabrication and cell attachment on scaffolds after sintering. (B) Number of
viable hMSCs and proliferation measured by the Prestoblue metabolic activity on day 3, 6 and 9 post-seeding (50,000 cells/scaffold). (C-E) SEM images of scaffolds
without cells (scale bar for C, D and E are 1 mm, 100 μm and 200 μm, respectively). (F-H) SEM images of cell-seeded scaffolds 3 days post-seeding (scale bar for F, G
and H are 1 mm, 100 μm and 200 μm, respectively). E and H images are of cut scaffolds showing internal morphology.
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out at different stages using Alkaline phosphatase (ALP) quantification
and quantitative gene expression analyses (Q RT-PCR) at week 1, OCN
staining and Q RT-PCR at week 2, and von Kossa staining at week 3.
ALP assays were performed on three types of scaffolds; blank scaf-
folds in OP media, blank scaffolds in OI media and GET-RUNX2 (RUNX)
loaded scaffolds in OP media. ALP levels, as measured by absorbance at
405 nm, were comparable between GET-RUNX2 loaded scaffolds and
the scaffolds in OI media and significantly higher than the blank scaf-
folds cultured in OP media (Fig. 4A).
OSTEOCALCIN (OCN) is a bone-specific protein synthesized by os-
teoblasts and its expression confirms full osteogenic commitment before
progression towards bone nodule formation [35–37]. OCN staining was
therefore conducted at day 14 post-fabrication (Fig. 4B). Expression of
OCN was visually comparable to scaffolds cultured in OI media and
those containing GET-RUNX2 loaded MPs. On the other hand, there was
minimal OCN expression observed in blank scaffolds seeded in OP
media (Fig. 4B). Mineralization was assessed using von Kossa staining
at day 21 (Fig. 4C). Bone nodules (black material) were visible in
scaffolds seeded in OI media and scaffolds containing P21-RUNX2-8R
loaded MPs. All tested scaffolds showed the white composite PLGA
scaffold, which was less evident in more differentiated conditions (with
GET-RUNX2 MPs or with OI) due to being coated with black von Kossa
stained mineral deposits.
Finally, we studied the molecular effects of GET-RUNX2 loaded MPs
on early and late osteogenic gene induction in hMSCs by Q RT-PCR
(Fig. 5). Significant activation of osteogenic genes could be observed in
GET-RUNX2 loaded cells in both week 1 and 2. As expected, GET-
RUNX2 loaded MPs released active P21-RUNX2-8R which induced en-
dogenous RUNX2 expression in hMSCs after week 1 (Fig. 5A). OSTERIX
(OSX), one of the prime target genes for RUNX2 is significantly
Fig. 4. hMSC osteogenic differentiation on PLGA/PEG scaf-
folds. Differentiation markers for hMSCs seeded on scaffolds
in osteo-permissive (OP) and osteo-inductive media (OI). (A)
Alkaline phosphatase (ALP) quantification at week one com-
paring blank and GET-RUNX2 MPs, with OI conditions and
without hMSCs as a control. (B) OSTEOCALCIN (OCN) im-
munostaining (red) with DAPI nuclear staining (blue) at week
2 (scale bar is 100 μm). (C) Von kossa-stained samples at week
3 (scale bar is 100 μm). Blank MPs represents cell seeded
scaffold containing blank MPs cultured in osteo-permissive
(OP) media. Loaded MPs represents cell-seeded scaffolds
containing P21-RUNX2-8R-loaded MPs cultured in osteo-
permissive (OP) media. OI media represents cell seeded
scaffolds containing blank MPs cultured in osteoinductive
media (OI). ** is P < .01.
Fig. 5. hMSC osteogenic gene expression analysis on PLGA/PEG scaffolds.
Blank MPs represents cell-seeded scaffold containing blank MPs, cultured in
osteo-permissive (OP) media. RUNX2-loaded MPs represents cellseeded scaf-
folds containing P21-RUNX2-8R loaded MPs, cultured in osteopermissive (OP)
media. OI represents cell-seeded scaffolds containing blank MPs, cultured in
osteo-inductive (OI) media. RNA was extracted from hMSCs at week 1 (A) and
week 2 (B) and gene expression analysis using Q-RTPCR was performed. The
results were plotted based on expression fold change to noninduced hMSCs on
blank scaffold using the ΔΔCT method. Data is presented as mean ± SE. * p.
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activated (8.2 fold over non-induced control; p < .05) in week 1 of
GET-RUNX2 loaded hMSCs (Fig. 5A). Expression of these two genes in
GET-RUNX2-loaded MP cells was similar to cells cultured on scaffolds
in OI medium (positive control). OSTEOPONTIN (OPN), a bone matrix
protein [38] however was lower in GET-RUNX2-loaded MP cells in
comparison to positive control cells at week 2 (Fig. 5B). This may be
due to the continuing release of RUNX2 which would be hypothesized
to delay terminal differentiation of the hMSCs in comparison to the OI
positive control.
3.5. hMSCs colonize the surface of PLGA/PEG scaffolds
We conducted SEM evaluation of scaffolds at day 21. Scaffolds
without cells (incubated in media for 21 days) were tested to evaluate
polymer degradation. The cell-seeded scaffolds showed less porosity as
the cells completely covered the surface as we have observed previously
[26]. Cells were seen to only grow significantly on the surface (as
shown in the scaffolds cut in half, Fig. S2C,F,I,L) which can be attrib-
uted to poor migration into scaffold pores as well as the lower porosity
of the prepared scaffolds. The media used (OP or OI) did not have an
overt impact on cell morphology, as in both cases the cells covered the
scaffolds with no noticeable difference (Fig. S2). The microstructure
evaluation of scaffolds (using micro (μ)CT) showed comparable results
between all scaffolds (Fig. S3). The cell distribution was mainly on the
surface of the scaffolds, with little cells within the scaffold structure, as
seen in SEM images of scaffold cross section (Fig. S2). This was similar
to previous extensive studies with cells on this material [26]. Specifi-
cally scaffolds that had the highest osteogenic differentiation; those
with GET-RUNX2 MPs (Fig. S3C) and those cultured in OI media (Fig.
S3D) had lower internal numbers of hMSCs (density of blue signal).
This may be expected as differentiating hMSCs will have, typically,
lower proliferation rates.
3.6. PLGA/PEG particles can be 3D printed by addition of Pluronic F127
Pluronic(P) F127 is a temperature-sensitive FDA approved polaxmer
[39], formulated as a triblock copolymer of poly (ethyleneoxide)/poly
(propyleneoxide)/poly (ethyleneoxide) [39–41]. PF127 has thermo-re-
versible gelation properties and has been widely used as cell carrier and
for various 3D printing applications [39–42]. At certain concentrations,
aqueous PF127 solutions gel at physiological temperatures [39]. In
order to develop a printable formulation of our system, the material
would have to possess a certain level of viscosity [43,44] that allows
continuous flow of the material through an extrusion printing head/
needle. Previously this material has been successfully combined with
several carriers to allow 3D printing, and sintering in the presence of
proteins and cells [27]. In order to achieve the needed viscosity, we
tested the use of PF127, pre-mixed before sintering with the PLGA/PEG
particles. PLGA/PEG successfully sintered in our groups previous stu-
dies [30]. No MPs were included at this stage to allow the optimization
of an extrudable formulation and printing process, once the parameters
had been optimized, the MPs were included into the system. Viscosity
for various concentrations of PF127 at different temperatures was stu-
died. It was concluded that suitable PF127 concentration for printing
should be between 15 and 20% (w/v). The temperature was fixed at
25 °C using a heated print head with PF127 being a gel at this tem-
perature and with sheer thinning suitable for printing (Fig. S4 shows
concentrations and ratios for printing and example tests). From our
analyses it was clear that the most suitable printing concentration was
18% (w/v) PF127 added in 1:1.5 ratio (PLGA/PEG particles:PF127)
which allowed extrusion and PLGA/PEG sintering. There was no ap-
preciable change in mechanical properties with handling of the sintered
PLGA/PEG scaffold with addition of PF127 at these concentrations.
PF127-containing scaffolds displayed compressive strength
(0.88 ± 0.06 MPa) (Fig. S5A) and elastic (Young's) modulus
(7.87 ± 0.01 MPa) (Fig. S5B), similar to previously published
(0.92 ± 0.05 and 8.76 ± 0.05) with four hours sintering [30]. A
further modification was developed to accelerate the sintering of
printed scaffolds containing PF127. Tri-acetin (1%) was added to the
PF127 solution; Tri-acetin is a plasticizer [45,46] and reduces the time
needed to stabilize scaffolds before media is added (from 2 h down to
30mins to remain intact). Addition of Tri-acetin to PF127-containing
scaffolds accelerated compressive strength (0.56 ± 0.09 verses
0.29 ± 0.03 MPa with and without, respectively at 30mins) (Fig. S5A)
and elastic (Young's) modulus (2.76 ± 0.03 verses 1.04 ± 0.04 MPa
with and without, respectively at 30mins) (Fig. S5B) [30]. Importantly,
although these values are lower than those obtained in other bone
tissue engineering studies, with harsher fabrication, they are none-
theless within the normal ranges for cancellous bone and the tissue is
thus, mechanically strong [21–24,27–30].
3.7. Scaffold integrity is retained with Pluronic F127 which can be removed
rapidly with low temperature washing
At a temperature of 37 °C, PF127 forms an unstable gel which
persists even when immersed in culture media for extended periods
[39] and can affect cell viability [40]. Therefore, we hypothesized that
PF127 would be best removed, and possibly this could be achievable by
diluting it away at lower temperatures.
Accordingly, scaffolds were washed in PBS at 4 °C for up to 45 min
after sintering and placed at 37 °C for 30 min. As a control to evaluate
the washing efficiency, scaffolds were also washed in PBS at 37 °C. It
was thought that if the washing process was not efficient at 4 °C, the
remaining PF127 would gel at 37 °C and the scaffolds would swell. The
scaffolds washed at 4 °C for over 10mins in cold PBS showed smooth
structure with no swelling (Fig. S7), on the other hand, scaffolds wa-
shed at 37 °C showed swollen structure with PF127 adsorbed on the
surface and the gel retained (Fig. S7). Mechanical testing of PF127-
containing scaffolds (with Tri-acetin) with and without cold PBS washes
showed minimal effect on both compressive (1.47 ± 0.08 verses
1.58 ± 0.07 MPa with and without, respectively at 4 h) (Fig. S6A) and
elastic (Young's) modulus of scaffolds(10.85 ± 0.26 verses
11.23 ± 0.12 MPa with and without, respectively at 4 h) (Fig. S6B).
Mechanical strength within the range of cancellous bone
[21–24,27–30] was therefore retained following PF127 removal.
3.8. hMSCs proliferate on scaffolds after removal of Pluronic F127
After optimizing the formulation for printing with the addition and
removal of PF127, it was important to determine the cell density op-
timal for printing, viability and differentiation, and to study the effect
of the whole process on cell viability and proliferation. Accordingly,
various cell densities were studied and cell proliferation was tested. The
scaffolds were prepared by mixing immortalized hMSCs (ihMSCs) with
PLGA/PEG particles (using 18% PF127 with 1% Tri-acetin at 1:1.5 ratio
(PLGA/PEG:carrier) formulation). The tested cell densities (0, 0.05, 0.1,
0.25, 0.5 and 1 × 106 per scaffold) were mixed, and the paste was
loaded into PTFE moulds and sintered at 37 °C. The scaffolds were then
washed in PBS at 4 °C for 45 min. Scaffold disintegration was evaluated
before and after washing by microscopy (Fig. S8A). The results showed
that intact sintered scaffolds (scaffolds were sintered for 30 min at
37 °C) remained intact after washing in PBS at 4 °C (Fig. S8A), in-
dicating that the sintering time was enough for the scaffolds to maintain
the structure and that PF127 removal did not significantly affect the
scaffold structure nor integrity. This mirrored the mechanical testing
previously demonstrating strong scaffold generation (Fig. S6 & S7)
[30]. Scaffolds were cultured in growth media at 37 °C, with PrestoBlue
cell metabolism assays performed to assess cell survival and prolifera-
tion (Fig. S8B). Increased initial cell concentrations resulted in en-
hanced cell retention in the scaffolds during washing and more robust
attachment and proliferation over the 10 day assessment (Fig. S8B).
Any cell number > 0.1 × 106 cells/scaffold showed effective
H.A.-D.M. Abu Awwad, et al. Journal of Controlled Release 325 (2020) 335–346
342
proliferation, with 1 × 106 cells likely to have saturated the scaffolds at
day 5–7 (with a plateau in metabolic activity). This demonstrated that
addition of PF127 and Tri-actin, sintering, washing and subsequent
culture was compatible with ihMSC viability and proliferation.
3.9. Successful cytocompatible bioprinting of hMSC-laden PLGA/PEG
scaffolds
The final aim of our studies was to fully confirm that the developed
system was a 3D bioprintable scaffold able to be co-printed with viable
stem cells and provide an osteopermissive hard yet porous structure for
bone regeneration applications. As a full demonstration, ihMSCs were
added to carrier (18% PF127 with 1% Tri-acetin) with final density of
1 × 107/ml (equivalent to 0.5 × 106/moulded scaffold) and mixed
with PLGA/PEG particles in 1:1.5 ratio at 4 °C. The mixture was then
loaded to the printing syringe and heated to 25 °C. The mixture was
then printed, and sintered at 37 °C for 30 mins. The sintered scaffolds
were then washed in cold PBS for 45 min and then cultured in media for
7 days. In order to test cell viability and proliferation, we again con-
ducted PrestoBlue cell assays on days 1, 3, 5 and 7 post-fabrication
(Fig. 6B). In addition, toluidine blue staining was carried out on day 7
to visualize cells directly on scaffolds (Fig. 6C&D). Cells demonstrated
proliferation with increased culture time relative to day 1 (Fig. 6B).
Toluidine blue staining showed distribution of the cells along the
printed scaffold strand (Fig. 6C), as well as within the strand, shown by
breaking and imaging a strand cross-section (Fig. 6D). Cells appeared
more densely populated within scaffolds due to the cells filling large
pores inside the material. To fully demonstrate the utility of our system
we 3D bioprinted a human-scale implant containing hMSCs (Fig. 7). We
modified a STL scan file of a male adult L5 vertebra (Fig. 7A&B); di-
viding the structure into two halves to allow compatibility with our
bioprinting system. We demonstrated the printing of the entire clini-
cally sized implant in< 8 mins (4 mins per half implant) (Fig. 7C,
Supplementary Video S1), which also incorporated complexity such as
overhangs and was several cm3 in size (~50 mm height). Implant
halves could be bonded with further cell-laden PLGA/PEG paste before
sintering (Fig. 7D). Again PF127 gel could be removed by cold washing
in PBS. This rapid prototyping of large personalized hard scaffolds,
containing hMSCs and a differentiation initiator is the first demon-
stration of such an approach.
3.10. Successful osteogenic hMSC differentiation in bioprinted scaffolds by
GET-RUNX2 release
To evaluate the differentiation response of hMSCs co-printed in 3D
printed PLGA/PEG scaffolds, we fabricated cell-laden scaffolds in-
corporating MPs. Both sintering and mechanical properties were similar
when MPs were added to the formulation, aligning with previous stu-
dies using MP sintering [13,31]. We next carried out differentiation
assays with hMSCs by using scaffolds containing GET-RUNX2 MPs
Fig. 6. hMSCs attach and proliferate within 3D bioprinted
PLGA/PEG scaffolds. (A) Schematic of hMSC-laden scaffold
fabrication with PF127, sintering and PF127 removal after
sintering. PLGA/PEG particles were mixed with 1% Tri-actin
and Pluronic 18% solution in 1:1.5 ratio. The solution was
mixed with hMSCs (1 × 107 per ml). The mixture was loaded
to the printing syringe and printed at 25 °C. After sintering at
37 °C and washing in cold PBS at 4 °C, scaffolds were then
cultured in media for 7 days. (B) Cell proliferation was eval-
uated by PrestoBlue assays at different time points for the
cultured scaffolds. Error bars indicate SD (n = 3). (C, D)
Toluidine blue stain for cells attached to the scaffold at day 7.
(C) Cells at the scaffold surface, and (D) internal staining by
breaking a scaffold strand. Scale bar is 1 mm. Data is pre-
sented as mean ± SD. * p < .01.
H.A.-D.M. Abu Awwad, et al. Journal of Controlled Release 325 (2020) 335–346
343
(60 μg/ml GET-RUNX2/ml mixture). Cell-laden scaffolds were cultured
in OP media, compared to those with blank MPs in OP or OI media, and
monitored for 21 days. Differentiation was assessed by OCN staining at
week 2, and von Kossa staining for mineralization at week 3 (Fig. S9;
black staining is mineralized nodules; white particles the PLGA com-
ponent). Results were comparable to those achieved without 3D
printing (Fig. 4), demonstrating no loss of osteogenic commitment
when cells were incorporated and 3D-printed within scaffolds, in
comparison with seeding the cells on the scaffolds after sintering. Bone
nodules (black staining, Fig. S9B) were observed with GET-RUNX2
which were comparable with that achieved without printing, or when
cultured in OI media. This confirms that GET-RUNX2 MP system could
be modified for bioprinting and could directly stimulate osteogenic
differentiation of hMSCs fabricated within scaffolds.
3.11. Regeneration of high density bone by GET-RUNX2 MPs in PLGA/PEG
scaffolds in vivo
A femoral drill-hole defect mouse model was used to assess the
ability of the PLGA/PEG scaffolds containing GET-RUNX2 MPs to in-
duce bone formation over a 6 week period (Fig. 8, Fig. S10). Human
STRO-1+ MSCs were added to scaffold and subsequently used to fill a
1 mm diameter drill-hole defect in the distal femur of athymic mice. In
vivo CT scans of the defect region were taken at the time of surgery and
additionally at 2, 4, and 6 weeks post-surgery in the same animal. The
diameter of the analysed defect is 1 mm, centred on the drill hole. The
depth of the defect is the thickness of the cortical bone (approx.
250 μm). The images captured were semi-transparent and represent the
bone density for the entire 3D reconstruction. This is a better re-
presentation of the bone formation rather than an offset thin disc
showing the thickness of the defect. The PLGA/PEG scaffold was not
visible as the scaffold does not absorb any x-ray energy at the levels
used for these scans. Although there was no apparent increase in the
total bone volume formed within the defect site (Fig. S10), there was an
increase in the volume of high density bone formed in GET-RUNX2
scaffolds at 4 weeks, and a significant increase by 6 week post-surgery
(Fig. 8B). The high density definition of bone generated here by GET-
RUNX scaffolds is based on the intensity of signal measured by μCT as
we have previously published [33] (lowest density bone set at 0.25 g/
cm3).
4. Discussion
GET-RUNX2 releasing PLGA MPs were prepared using S/O/W with
high encapsulation efficiency as previously published [13]. We ac-
celerated the protein release by incorporating PBS during the for-
mulation. PBS works as a porogen, increasing MP porosity by gen-
erating channels within and on the MP surface [13,31]. Above 90% of
the encapsulated P21-RUNX-8R was released in the first 7 day period
(Fig. 1E). This release profile was developed to match the previous
findings of dose requirements of GET-RUNX2-triggered osteogenic dif-
ferentiation of hMSCs (i.e. two doses of 30 μg/ml in the first week of the
study) [9].
The challenging issues in controlled release system are en-
capsulating and releasing molecules that remain biologically active
[47,48]. We have previously shown that GET peptide activity is com-
promised in the presence of carboxylic acid groups produced upon
PLGA degradation. The use of L-Histidine was shown to maintain the
activity of GET peptides upon release [13]. Consequently, L-Histidine
was added to the formulation with the encapsulated P21-RUNX2-8R. In
order to validate the biological functionality for P21-RUNX2-8R post-
release, the transduction and subsequent transcriptional activity of the
released protein was tested. The results showed that the released P21-
RUNX2-8R has activity comparable to the experimental controls, con-
firming our previous findings and validating the delivery system for
targeted delivery of such therapeutic molecules.
Scaffolds were formed by mixing thermo-sensitive PLGA/PEG par-
ticles with blank or GET-RUNX2 loaded MPs. PBS was used to create a
paste-like material, this was packed in PTFE moulds and incubated for
2 h at 37 °C for sintering. This osteoconductive technology was pre-
viously described [26,30] and been demonstrated as 3D printable [27].
However the biomaterial had not been used to program osteogenic
differentiation of hMSCs, or employed with GET technology in-
corporated. The use of this biodegradable polymer along with the GET
Fig. 7. 3D bioprinting of an L5 human adult lumber
vertebra. (A) L5 human adult vertebra (25 mm
height, 50 mm width) (highlighted in green) was
chosen to demonstrate rapid 3D bioprinting of
hMSC-laden PLGA/PEG scaffold as a personalized
implant. (B) STL file of the L5 vertebra was divided
into two halves for 3D bioprinting. (C) Half L5 ver-
tebrae were fabricated in less an 4 min (240 s). (D)
L5 vertebrae halves could be bonded with further
PLGA/PEG paste (PLGA/PEG mixed with 1% Tri-
acetin and 18% PF127 (1:1.5 ratio) and ihMSCs),
sintered and cold washed to generate an hMSC-laden
personalized scaffold. Scale bars are 20 mm. (For
interpretation of the references to colour in this
figure legend, the reader is referred to the web ver-
sion of this article.)
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peptide controlled release delivery system would allow new in-vivo
applications, especially in bone regeneration. The ability to paste the
scaffold at a defect site can offer improved clinical translation when
compared to metallic implants [1]. Moreover, this material can be
formulated with simple addition of PF127 and Tri-acetin to be 3D
printable as demonstrated here; which gives the ability to fill complex
and difficult to reach geometric defects or as a pre-fabricated implant
[2].
PLGA/PEG scaffolds have potential to be used in vivo. Firstly the
ability of hMSCs to attach, proliferate and differentiate on scaffolds in
vitro was assessed. The results showed effective attachment and pro-
liferation of hMSCs on the scaffolds over a 9-day period, confirming
cytocompatibility. Next, to prove these scaffolds could host osteogenic
differentiation of hMSCs using GET-RUNX2 loaded MPs, we conducted
several cell differentiation studies comparing pre-sintered (Fig. 4) and
3D printed systems (Fig. 7). Differentiation markers showed compar-
able behaviour between scaffolds containing P21-RUNX2-8R loaded
MPs and the scaffolds cultured in osteo-inductive (OI) media. Differ-
entiation was comparable between pre-sintered and 3D printed scaf-
folds (Figs. 4 and 7). Encapsulation of genetically targeted biologics
such as TFs in scaffolds should prevent off-target pleiotropic side-effects
such as seen with high dose steroid or growth factor stimulation, should
reduce the loss by diffusion of such regulatory molecules and will en-
able safe and effective tissue engineering strategies to be developed
[3,4]. The results show that GET-RUNX2 can induce it's own en-
dogenous RUNX2 expression (Figs. 4 and 7) compared to the samples
containing no RUNX2. These findings, here in 3D scaffold structures,
are comparable to our previous 2D differentiation findings using GET-
RUNX2 to program hMSCs [9]. The use of GET-RUNX2 loaded MPs will
help in targeted stem cell reprograming, directly delivering the stimulus
needed to induce the expression of osteogenic target genes. This
strategy of delivering specific factors for promoting bone formation also
helps in preventing undesirable, undirected differentiation which
sometimes can see adipose or chondrogenic lineage induction and not
osteogenesis from hMSCs, minimizing off-target or systemic side-ef-
fects. Our work culminated in demonstrating high-density bone re-
generation in a mouse model which shows that the full system can have
in vivo benefit in a formulation compatible with cells and additive
manufacturing. Future work will apply the system to larger pre-clinical
animal studies using more complex scaffold implants to confirm the
mechanical and biological efficacy at human-sized scales.
5. Conclusion
A robust method of fabricating GET-RUNX2-loaded MPs using S/O/
W emulsion technique was utilized providing a controlled release
system. MPs were mixed with temperature sensitive materials that can
solidify at body temperature providing a ‘cancellous bone-like’, me-
chanically strong scaffold that can fill a bone defect inside the body or
generate personalized implants. hMSCs seeded on or within these
scaffolds can be induced towards osteogenesis in response to the TF
RUNX2 released from the co-formulated MPs. This delivery technology
has potential to be valuable in the controlled delivery of various potent
therapeutic molecules, including recombinant proteins coupled with
GET peptides. We believe that our improved methods to generate hard
osteoconductive, 3D bioprinted porous scaffolds that promote hMSC
growth and osteogenesis in one combined formulation, has the poten-
tial to become a patient-applicable translational technology. Such in-
tegrated systems will be vital for new innovative classes of personalized
cell-based therapies and regenerative medicine for treating trauma and
disease to be exploited.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jconrel.2020.06.035.
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